LILLE & PARIS, France, Aug. 4, 2026
4Moving Biotech (4MB) announced the completion of patient enrollment in the Phase 2a INFLAM MOTION clinical trial evaluating 4P004, a first-in-class investigational intra-articular GLP-1 receptor agonist for patients with knee osteoarthritis associated with synovitis. The international randomized, double-blind, placebo-controlled study enrolled 129 patients across Europe, the United States, and Canada, targeting an inflammatory disease phenotype linked to pain, structural progression, and an increased risk of knee replacement. Unlike conventional osteoarthritis therapies focused primarily on symptom relief, 4P004 is designed to directly target the inflammatory mechanisms driving both pain and disease progression while minimizing systemic exposure through localized administration. The company expects topline results by the end of December 2026.
Phase 2a Trial Evaluates Clinical Outcomes and Imaging Biomarkers
The INFLAM MOTION study randomized patients with contrast-enhanced MRI-confirmed synovitis to receive a single 2 mg intra-articular injection of 4P004 or placebo, followed by a three-month evaluation period. The trial specifically selected patients based on the presence of synovitis, rather than obesity status, to evaluate a patient population associated with a higher likelihood of disease progression. The primary endpoint is reduction in knee pain at Week 4, while key secondary endpoints include changes in synovial tissue thickness, overall synovitis burden measured by contrast-enhanced MRI (CE-MRI), knee pain at Week 12, imaging biomarkers, and circulating biomarkers associated with osteoarthritis progression. The study combines patient-reported outcomes with objective biological assessments to better understand whether local GLP-1 receptor activation can modify inflammatory disease pathways.
First-In-Class GLP-1 Therapy Targets Disease Progression
Unlike traditional osteoarthritis clinical trials, INFLAM MOTION integrates advanced imaging biomarkers to evaluate whether reducing synovial inflammation translates into both symptomatic improvement and measurable biological changes linked to disease progression. Growing scientific evidence identifies synovitis as a major driver of knee pain and structural deterioration in osteoarthritis, making it an important therapeutic target. By acting directly inside the affected joint, 4P004 aims to selectively reduce inflammation while limiting systemic drug exposure. Researchers expect the study to generate one of the most comprehensive datasets evaluating the relationship between clinical outcomes, MRI imaging biomarkers, inflammatory biology, and local GLP-1 receptor activation, potentially supporting a differentiated disease-modifying approach for osteoarthritis.
Advertisement
Results Will Guide Phase 2b Development and Regulatory Strategy
Completion of enrollment marks an important milestone as 4Moving Biotech transitions the program into patient follow-up and preparation for clinical data analysis. The company expects the Phase 2a topline results before the end of December 2026, with findings intended to guide the design of the subsequent Phase 2b trial. In addition to evaluating clinical efficacy, the results are expected to support future regulatory interactions by providing evidence of both clinical benefit and objective biological activity relevant to disease modification. If successful, 4P004 could represent a novel therapeutic strategy that moves beyond symptom management toward addressing the underlying inflammatory processes responsible for knee osteoarthritis progression, potentially offering a first-in-class treatment option for patients with the synovitis-associated inflammatory phenotype.
Source: 4Moving Biotech press release
